Genomic Health and W2O

Put Chemo to the Test

While one in eight U.S. women will develop breast cancer, not every patient benefits from chemotherapy. The TAILORx study, the largest ever conducted in breast cancer, proved that Genomic Health’s Oncotype DX Breast Recurrence Score test can tell whether or not chemo is the best option. With its clean design and compelling story, empowers women to ask for the test and understand their treatment options.